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INTRODUCTION
According to the Centers for Disease Control and Prevention, more than ninety people
die each day from opioid overdoses. Opioid overdoses accounted for two‐thirds of drug overdose
deaths within the United States in 2015. Death rates have also increased steadily since the 1990s
across all socioeconomic, ethnic, and age groups despite a nineteen‐percent decrease in opioid
prescribing rates.1,2 There are still almost fifty‐eight opioid prescriptions written for every one‐
hundred Americans and an average of 3.4 prescriptions dispensed per patient.3,4 Chronic pain
disorders represented a substantial economic and health burden due to lost productivity and
increased health care usage.1,2
Possible solutions to the opioid epidemic have shown variable success. These solutions
include limiting coverage on prescriptions, increased training and education to providers,
required use of pain management contracts, and improved community resources. Solutions have
also included the increased use of opioid partial agonists‐antagonists, like buprenorphine, and
opioid antagonists, like naloxone. There has also been an increase in the use of alternative
therapies, such as physical therapy, massage, and chiropractic adjustments. One ethically
controversial therapy that is undergoing increased research recently, is the use of placebos in the
treatment of chronic pain. While there is a considerable amount of research that corroborates
the beneficial effects of placebo analgesia in the treatment of depression and irritable bowel
syndrome, few exist for chronic pain.4 The placebo effect refers to positive clinical results caused
by a treatment that is not attributable to its known mechanism of action or physical properties.
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It is often explained because of positive expectations instilled in patients derived from outcomes
of previous clinical encounters.5 Placebo analgesia is often used deceptively, without consent,
and with little evidence of benefit.6
Little is known regarding how the use of placebo analgesia compares to opioids affect
long‐term treatment efficacy in patients with chronic non‐cancer pain over the first two years of
treatment. To best answer this question, one must understand the transition from acute to
chronic pain along nociceptive signaling pathways. This literature review aims to describe the
major nociceptive signaling pathways involved in opioid and placebo analgesia and to discuss
how placebo treatment affects chronic pain undergoing central sensitization. It will also review
the current understanding of placebo effect and discuss the effects of dose‐extending placebo
use of opioid tolerance.
NOCICEPTIVE OPIODERGIC PATHWAYS
Pain sensation is evoked through protopathic pathways carrying temperature and
pressure input from the skin through the spinal cord to the brain. Nociceptors are excitatory
neurons that release glutamate for primary neurotransmission, as well as, other components
including peptides, such as substance P, calcitonin gene‐related peptide, and somatostatin. Most
nociceptors are unmyelinated free nerve endings with small diameter axons (C and Aδ‐fibers).
Their peripheral afferent innervates the skin and projects to the posterior marginal nucleus and
substantia gelatinosa of the posterior horn of the spinal cord. The signal ascends through the
contralateral lateral spinothalamic tracts and splits partially going to the ascending reticular
activating system and part to the central posterolateral nucleus of the thalamus where crude
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pain is conveyed. From the ascending reticular activating system, it is transmitted to the limbic
system, as well as, activating the sympathetic nervous system. From the thalamus, it then
ascends to the post‐central gyrus where location and quality are conveyed.7
The descending pathway in pain inhibition appears to primarily descend through the
periaqueductal gray to the nucleus raphe magnus and act on the substantia gelatinosa and
nucleus proprius through opioidergic signaling induced from the epicritic pathway (i.e., gate
control theory) and periaqueductal gray (produces enkephalin) and rostral cingulate cortex.7,8
Most of the inhibition appears to occur through local excitatory and inhibitory interneurons in
the posterior horn and descending pathway due to opposing signaling priority from homeostatic
demands and extrasensory perception. These pathways are the serotonergic‐noradrenergic and
opioidergic pathways which activate GABAergic/glycinergic depolarization of presynaptic
terminals leading to the dorsal root reflex and transmission of an action potential resulting in the
release of inflammatory mediators in the skin that intensify nociceptor excitability.9
CENTRAL SENSITIZATION
Many quantitative sensory testing studies on pain show that many chronic pain
conditions, including migraine headache, osteoarthritis, and chronic visceral conditions can
undergo central sensitization.10 Central sensitization occurs when the nervous system is placed
in a persistent state of high reactivity. In this state, the threshold as to what is relayed as pain is
lowered and consequently, a state of pain is maintained even after the initial injury has healed.
This process seems to occur through temporal and spatial summation. Repeating high‐frequency
afferent signaling results in increased pain intensity. If a painful stimulus is repeated multiple
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times for a set period, the pain will integrate and become more painful toward the end of the
stimulus. In addition, pain is increased when the area of painful stimulus is increased.11
Predisposing factors to central sensitization are likely both biological and psychological. While
there is no research linking pre‐existing pain tolerance thresholds and development of central
sensitization, it is mainly assumed one exists. Also, psychological factors, such as individual stress‐
responses appear to predispose patients for lowered pain thresholds. There appears to be a
correlation between patients with a history of increased anxiety and the development of chronic
pain.12
PLACEBO EFFECT
Research into placebo analgesia has been divided on whether placebo effects depend on
conscious expectancy or learning mechanisms. Several studies have tried to answer this
dispute.13 Popular theories suggest that conditioning is released to both initial expectancies and
association‐based changes, in other words, the patients’ expectations of the treatment and their
past experiences with similar treatments. Rescorla and Wagner14 theorized that conditioning
depends on prediction error – discrepancies between expected and observed outcomes. They
found that reward prediction errors amount to the difference between received and predicted
reward.
It has also been shown that the analgesia benefit in subjects was enhanced when the
placebo followed the actual control treatment session. In those subjects that experienced the
placebo treatment first, the control treatment’s analgesic effects were reduced, or subjects
perceived an increased response to the pain stimulus. The analgesic effects were significantly
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greater when it followed a successful active session than when the preceding treatment was
ineffective, in other words, the subject’s expectation appears to affect the treatment efficacy
regardless of whether the treatment is active or placebo15.
In an experiment by Pecina et al13, it was found that comparisons between expected and
observed outcomes are an indicator of sustained placebo effects. They compared the expectation
of pain followed by a non‐painful condition, which was then followed by a painful condition
applied to the masseter muscle. Subjects were told that they would receive a painful stimulus
and a non‐painful stimulus over a twenty‐minute period, but not the order. The subjects also
received medication to relieve the painful stimulus. Volunteers would rank their expectation of
the medication, rate their perceived pain on a pain visual analog scale at set intervals, and
afterward rate the perceived effectiveness of the medication. The results were incongruent with
classical theories where the formation of placebo responses was dependent on the development
of positive expectations. The largest placebo responses were in those with low expectations and
high subjective effectiveness. In other words, the longest lasting and greatest placebo analgesia
occurred in subjects that did not expect much from the treatment. They theorized that this
correlated with Rescorla and Wagner’s theory that prior positive experience may act to condition
the procedure inducing an increased analgesic effect following placebo treatment; while an
unpleasant previous experience reduced the analgesia active treatment or induces a nocebo
effect.
While positive expectations appear to have an unexpected effect on placebo analgesia,
outcomes seem to be directly related. In a study by Colloca and Benedetti, 16 participants were
given a placebo analgesic treatment and told that they would receive a reduction in pain (thermal
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stimulation). Those in the experimental group would receive a lower temperature stimulus to
imply effective treatment, while those in the control received the same stimulus. In subsequent
stimuli, pain was perceived as reduced in the experimental group, even though the stimulus
temperature increased.
A meta‐analysis of studies using neuroimaging data on placebo analgesia showed that
placebo treatments have modest effects on patient reports of pain, but minimal effects on
responses in nociceptive pathways.17 In the evaluation of the intensity of pain and the response
of the nociceptive pathways, they noticed little change in imaging data, but changes in participant
response. They concluded that this indicates that there are other processes involved in
nociceptive pain response, which they call extra‐nociceptive pathways. It is possible that placebo
analgesia may affect pain perception along another system. They did note that a limitation to all
the studies evaluated was the use of healthy participants and that they may not generalize clinical
pain.
It is still possible that the intensity of the placebo intervention used could have a variable
effect on analgesia; however, in a systemic review by Fassler et al18 found no significant
difference in interventions – whether there was a difference in intensity or invasiveness. They
looked at twelve studies with 1,059 participants utilizing various routes of placebo. Their study
was limited due to the heterogeneity of the studies lengths, and there was no statistical
difference between groups regarding placebo dose. To account for these differences, they limited
their analysis to patient outcomes. Their data were also limited by the small number of studies
involved and the variability of disorders evaluated (e.g., chronic pain, irritable bowel syndrome,
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vaginal pain, and anxiety). It is notable that their data reflect what Zunhammer and his
colleagues17 found regarding little changes in nociceptive pain response.
TOLERANCE AND PLACEBO DOSE‐EXTENSION
A new area of research is the congruent use of placebo with active medication treatment
in which the placebo is given after an effective treatment in a repetitive manner. The placebo
mimics the psychologic and biologic responses that are associated with the effectiveness of the
medications and reducing the side effects, overall costs and reducing tolerance.19 Dose‐extending
placebo could be used to exploit endogenous pain modulatory processes. Colloca and colleagues5
concluded that placebo could be used therapeutically by integrating it into the therapeutic
schedule. They conducted a systematic review of twenty‐two studies (consisting of animal and
human studies) and found that placebo integration reduces total drug intake and limits dose
escalation over time. They found that placebos that were given after scheduled active treatment
mimic pain reduction in both animals and humans. Their research corroborated a study by Ader
and colleagues20; it was shown that the relapse of psoriasis following a full dose of
corticosteroids, a half‐dose with congruent placebo, and placebo alone was 22.2%, 26.7%, and
61.5%, respectively. While research into dose‐extension in analgesia is developing and limited by
small sample sizes, there could be possible therapeutic strategies in some patients.
FUTURE DIRECTIONS
While the physiology of placebo analgesia is still not well understood, there is evidence
that it has a place in the treatment of chronic non‐cancer pain. Placebo effect can contribute to
positive clinical outcomes. There is also growing evidence that it can modulate the course of
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concurrent opioid therapy through dose‐extension. Placebo effect appears to benefit from
learned mechanisms, as well as, subconscious expectations as the outcomes of placebo analgesia
are altered by clinician‐patient social interactions, classical conditioning, and how the
information regarding the treatment and its outcome is framed.6,7,21
It is unclear whether placebo analgesia is acceptable in clinical use. There still many
questions regarding the ethics of using placebo treatments.14,19 While a 2008 survey by Tilburt
and colleagues22 of US internists and rheumatologists found that about half of respondents
admitted that they have prescribed a placebo to patients, there is still no consensus on whether
it is acceptable. There are currently few studies on the use of open‐labeled placebo (placebo
without deception), and most lack large sample sizes. The studies also appear to suffer some level
of bias due to the Hawthorne effect, which may be unavoidable due to the inability to blind the
subjects.21,23,24 There are still other ethical concerns to consider. While open‐label placebo
removes the need to deceive the patient, it is questionable there are no harms in prescribing an
inactive agent.
Further inquiry into the relationship between placebo and pain processing is necessary to
verify the current understanding of neurophysiologic effects on pain response21. In addition,
longitudinal studies with larger sample sizes utilizing open‐label placebo are needed to help
alleviate current limitations of sample size and bias from lack of blinding researchers and
subjects. Current research into dose‐extension and open‐label placebo all include small samples
and short durations. In addition, further analysis of biological variables, including twin studies,
are needed to explain interindividual variability in response to placebo25.
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This review set out to describe the major nociceptive pain pathways involved in placebo
analgesia, as well as, the current understanding of placebo effect on concurrent opioid use. After
reviewing the literature, one can be cautiously optimistic on the future clinical use of placebo
analgesia as a tool in the treatment of chronic non‐cancer pain, especially in the presence of
opioid dependence as a possible adjunct in decreasing opioid dosage. The current use of placebo
in the treatment of chronic non‐cancer pain; however, should include a thorough discussion and
mutual consensus between provider and patient.
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